Artificial Enzymes Perform Reactions On Living Cells
News Jul 26, 2018 | Original story sourced from the American Chemical Society
Photo credit: Pixabay
Nature has evolved thousands of enzymes to facilitate the many chemical reactions that take place inside organisms to sustain life.
Now, researchers have designed artificial enzymes that sit on the surfaces of living cells and drive reactions that could someday target drug therapies to specific organs. They report their results in the Journal of the American Chemical Society.
Metalloenzymes are a class of enzymes that contain a metal ion, such as zinc, iron or copper.
The metal ion helps the enzyme catalyze chemical reactions that would otherwise occur very slowly or not at all.
Scientists would ultimately like to develop a method to produce therapeutic drugs only at the sites of specific cells or organs of the human body, which could reduce side effects, and enzymes could help them reach that goal.
Wadih Ghattas, Jean-Pierre Mahy and their colleagues set their sights on engineering an artificial enzyme that could catalyze a useful reaction, called the Diels-Alder reaction, right on the surfaces of living cells. Chemists use this reaction to synthesize drugs, agrochemicals and many other molecules.
To make their artificial enzyme, the researchers began with a protein called the A2Aadenosine receptor, which is naturally present on the surfaces of some cells in the body.
They modified a molecule that binds to this receptor with a copper-containing chemical group that catalyzes the Diels-Alder reaction.
When the researchers placed the resulting compound in a culture dish containing living human cells, it attached to the A2A adenosine receptors on the cells, forming an artificial enzyme.
This enzyme catalyzed the Diels-Alder reaction with an up to 50 percent increase in yield.
The researchers say that in the future, artificial enzymes might be designed that bind to proteins found only on specific cell types, for example, cancer cells.
Then, the enzyme could convert an inactive compound into a drug to selectively kill those cells.
This article has been republished from materials provided by the American Chemical Society. Note: material may have been edited for length and content. For further information, please contact the cited source.
Ghattas, W., Dubosclard, V., Wick, A., Bendelac, A., Guillot, R., Ricoux, R., & Mahy, J. (2018). Receptor-Based Artificial Metalloenzymes on Living Human Cells. Journal of the American Chemical Society, 140(28), 8756-8762. doi:10.1021/jacs.8b04326
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE